J&J to provide U.S. with 100M doses of COVID-19 vaccine

By The Science Advisory Board staff writers

August 5, 2020 -- Johnson & Johnson will manufacture and deliver 100 million doses of its SARS-CoV-2 investigational vaccine to the U.S. government once it receives regulatory approval from the U.S. Food and Drug Administration (FDA).

Funding of over $1 billion will be provided by the U.S. Biomedical Advanced Research and Development Authority (BARDA) in collaboration with the U.S. Department of Defense. Under the agreement, the vaccine, Ad26.COV2.S, will be provided at a global not-for-profit basis for emergency pandemic use. The U.S. government may also purchase an additional 200 million doses under an additional agreement.

The company is conducting research and development in collaboration with BARDA and oversight from the FDA. Recently published phase I/IIa clinical trial results were positive and the company is currently evaluating both one- and two-dose regimens.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here